Compare Immunovant Inc. Common Stock (IMVT) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs State Street SPDR S&P Homebuilders ETF — how do they compare? Immunovant Inc. Common Stock trades at $30.47 (market cap $6.25B), while State Street SPDR S&P Homebuilders ETF trades at $94.83 (market cap $1.49B). The key difference: Immunovant Inc. Common Stock is far larger — about 4.2× State Street SPDR S&P Homebuilders ETF's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 1 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| IMVT | XHB | |
|---|---|---|
Market Cap | $6.25B | $1.49B |
Volume | 1,755,411 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $44.96 | $121.36 |
52-Week Low | $17.03 | $94.86 |
Typical Hold Time | 1 Days | 33 Days |
Enterprise Value | $5.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XHB (SPDR S&P Homebuilders ETF) trades at $94.77, down 0.13% with a bearish technical outlook from moving averages. The ETF tracks homebuilder stocks facing headwinds from rising mortgage rates near 7%, though recent news highlights potential buying opportunities amid sector undervaluation. Technical indicators show neutral oscillators but bearish momentum with support at $94 and resistance at $96.
The housing market faces mixed signals with rising rates pressuring affordability, but legislative support and institutional interest suggest long-term potential. Key risks include mortgage rate volatility and economic sensitivity, while analyst coverage emphasizes sector recovery prospects. Investment appeal hinges on housing market stabilization and policy impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
